Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination lock01
2024-514042-36-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amikacin in sepsis, septic shock, bacterial disease and 2 more (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Day-90 mortality. Planned start Aug 2024; status: authorised.
02
Drugs
amikacin
03
Conditions
sepsisseptic shockbacterial diseaseviral infectionmycoses
Beyond the preview
Go deeper on 2024-514042-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514042-36-00.